34 Lives

34 Lives, based in West Lafayette, Indiana, is a biotechnology company focused on revolutionizing kidney transplantation by rehabilitating donated kidneys that would otherwise be discarded. The company’s proprietary technology enables the safe extension of preservation times by restoring kidneys to near-normal body temperatures, allowing for functional assessment and improving transplant viability. This innovation addresses the critical shortage of transplantable kidneys, directly benefiting the over 96,000 patients awaiting kidney transplants in the U.S. Formerly known as Renovera, 34 Lives has positioned itself at the forefront of organ preservation and transplantation science, leveraging advanced biotechnological methods to enhance organ recovery and reduce waste. The company successfully secured seed funding in October 2022, supported in part by government grants such as SBIR, underscoring its potential and credibility in the biotech and healthcare sectors. While no patents or major private investors have been publicly disclosed, 34 Lives’ unique value proposition lies in its ability to increase the availability of life-saving kidneys, potentially transforming transplant outcomes. Future initiatives may include expanding collaborations with transplant centers and further refining preservation technologies, aiming to broaden the scope of rehabilitated organs and improve long-term patient survival rates. As such, 34 Lives stands as a promising innovator addressing a vital unmet need in organ transplantation.